Sansheng Huatan Decoction combined with chemotherapy is a better treatment for non-small-cell lung cancer as compared with chemotherapy.

Key indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.003 Å; R factor = 0.032; wR factor = 0.077; data-to-parameter ratio = 16.3. organic compounds o3320 # 2007 International Union of Crystallography Comment 1-Methyl-4-methylsulfonyl-2-nitrobenzene is an important intermediate for the synthesis of Mesotrione which is a useful corn herbicide for pre-and post-emergence control of grass and broadleaf weeds (Wichert et al., 2006). It was obtained by the alkylation and nitration of 4-methylbenzenesulfonyl chloride.The molecular structure of (1) is illustrated in Fig. 1. Atoms C1, C2, C3, C4, C5, C6, C7, N1 and S1 are coplanar, the largest deviation being 0.0415 (13) Å for C7. ExperimentalThe title compound was prepared according to the procedure of Brown (1991) and Katz et al. (1953). A solution of the compound in ethanol was concentrated gradually at room temperature to afford colourless chunks (m.p. 391-392 K). RefinementH atoms were added at calculated positions and refined using a riding model. H atoms were given isotropic displacement parameters equal to 1.2(or 1.5 for methyl H atoms) times the equivalent isotropic displacement parameters of their parent atoms and C-H distances were restrained to 0.93 Å for those bonded to phenyl ring, 0.96 Å for those bonded to methyl.

Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) was first discovered in 1987 and confirmed to be a protein that is mainly expressed on the surface of activated lymphocytes. CTLA-4 is expressed on the surface of T cells and binds to B7 expressed on antigen presenting cells(APCs) to potentially play a role in inhibiting lymphocyte proliferation. Inhibitors of CTLA-4 were developed to promote the anti-tumor effects of T cells and inhibit tumor growth. CTLA-4, as an immune checkpoint, has been realized as an important therapeutic target in bladder cancer. Two main CTLA-4 inhibitors are currently used: ipilimumab is a first-generation IgG1 monoclonal antibody that targets CTLA-4, and it is completely synthetic; tremelimumab, representing another class of CTLA-4 inhibitors, is a monoclonal antibody against CTLA-4 that acts similarly to ipilimumab and binds specifically to CTLA-4. The two types of CTLA-4 inhibitors were found to improve the treatment effect in patients with bladder cancer in comparison to conventional agents. To review this topic, we searched recently published related articles.